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Although several non-alcoholic steatohepatitis (NASH)
models have been reported to date, few of these models
fully reﬂect the histopathology and pathophysiology of
human NASH. The aim of this study was to establish a
novel NASH model by feeding a high-fat (HF) diet and
administering both carbon tetrachloride (CCl4) and the
Liver X receptor agonist T0901317. Male C57BL/6J mice
were divided into four groups (each n¼ 5): HF, HFþ
CCl4, HFþT0901317, and the novel NASH model (HFþ
CCl4þT0901317). CCl4 (0.1mL/kg) and T0901317 (2.5mg/
kg) were intraperitoneally administered four times and
ﬁve times, respectively. The livers of the novel NASH
model group presented a whitish colour. The serum
levels of TNF-a and IL-6 were signiﬁcantly increased in
the novel NASH model group, and mice in this group
exhibited histopathological features and insulin
resistance reﬂective of NASH, i.e., macrovesicular
hepatic steatosis, ballooning hepatocytes, Mallory-Denk
bodies, lobular inﬂammation and ﬁbrosis. The novel
NASH model group presented signiﬁcantly upregulated
expression levels of mRNAs related to lipogenesis,
oxidative stress, ﬁbrosis and steatosis and signiﬁcantly
downregulated expression levels of mRNAs related to
triglyceride export. We successfully established a novel
experimental NASH model that exhibits similar
histopathology and pathophysiology to human NASH.
Key words: insulin resistance, Liver X receptor, mouse
model, NAFLD activity score, non-alcoholic steatohepatitis
Metabolic syndrome has been increasing worldwide con-
comitant with the increased prevalence of obesity, diabetes
mellitus, and hyperlipidemia. Non-alcoholic fatty liver dis-
ease (NAFLD) was recently recognized as a hepatic
manifestation of metabolic syndrome.1 NAFLD consists of
simple hepatic steatosis and NASH.2 NASH is diagnosed
using only histopathological ﬁndings, i.e., hepatic steatosis,
ballooning hepatocytes, lobular inﬂammation and perisinu-
soidal ﬁbrosis. Currently, NAFLD is present in 20–40% of
the general population of industrialized countries.3,4 Among
all patients with NAFLD, features of NASH are observed in
10–20%.5,6 Thus, NAFLD is considered a common chronic
liver disease. Because studies of NASH using human
materials are limited by ethical concerns regarding the
administration of drugs to patients or the collection of liver
tissues from patients, the pathogenesis of NASH is currently
not well understood, and treatments for NASH have not
been established.
In recent years, many experimental NASH models have
been reported.7–11 The methionine-/choline-deﬁcient (MCD)
model has been widely used for basic studies of NASH.12
The advantage of the MCD model is that it can rapidly
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induce steatohepatitis in mice. After three weeks of MCD
feeding, steatohepatitis is well developed, and after 8–10
weeks, pericellular and perisinusoidal ﬁbroses are pres-
ent.13 The disadvantages of this model are that the mice
exhibit a dramatic body weight loss and do not develop
insulin resistance.13,14 As a result, these features of the
MCD model do not fully reﬂect the clinical features of
human NASH.
A high-fat (HF) diet model is also widely used for the
basic study of NASH because it causes obesity and insulin
resistance.15 In the HF diet models, long-term feeding of a
HF diet leads to steatohepatitis that resembles that ob-
served in human NASH.16 However, this model is not
suitable for researching the pathogenesis of NASH because
a long time is required for the development of NASH
symptoms and because the hepatic ﬁbrosis in the model
animals is weaker than that found in human NASH.16
Therefore, the establishment of a novel animal model that
exhibits features similar to those of human NASH is
necessary for the basic study of NASH.
We aimed to develop a novel NASH model by feeding an
HF diet and administering both carbon tetrachloride (CCl4)
and T0901317, which resulted in a combination of multiple
important factors, including overnutrition, oxidative stress
and lipogenesis. The administration of CCl4 is known to
induce chronic oxidative stress and liver injury in mice, and
CCl4 has been used to create acute hepatitis animal
models.17 An analysis of histopathological ﬁndings has
revealed that CCl4 leads to inﬂammation and ﬁbrosis but
not steatosis or ballooning. The liver X receptor (LXR) is a
nuclear receptor that plays a key role in regulating
cholesterol, fatty acid and glucose metabolism.18 The LXR
activator T0901317 has been recognized as a potential
target for the treatment of atherosclerosis. However,
T0901317 produces several severe side effects, including
hepatic steatosis.18
The aim of this study was to establish a novel NASH
model with histopathological and insulin-resistance features
similar to those of human NASH.
MATERIALS AND METHODS
Animals
Six-week-old male C57BL/6J mice were obtained from
Charles River Laboratories JAPAN, Inc. (Kanagawa, Japan)
and were acclimated for one week before the start of the
experiment. The mice were maintained under a 12 h light-
dark cycle and had free access to standard chow and tap
water. The animal experiments were conducted in a
humane manner after receiving approval from the
Institutional University Experiment Committee of the
University of Tsukuba and in accordance with the Regu-
lations for Animal Experiments of the university and Funda-
mental Guidelines for Proper Conduct of Animal Experiment
and Related Activities in Academic Research Institutions
under the jurisdiction of the Ministry of Education, Culture,
Sports, Science, and Technology.
Experimental groups
Twenty mice were divided into the following four groups
(n¼ 5 per group): (i) the mice in the HF group were fed an
HF diet (60 kcal% fat, D12492, Research Diets, Inc., New
Brunswick, NJ, USA) for four weeks; (ii) the mice in the
HFþCCl4 group were fed an HF diet for four weeks and
administered CCl4 (Wako Pure Chemical Industries, Ltd.,
Osaka, Japan) intraperitoneally (i.p.) twice a week for the
ﬁnal two weeks; (iii) the mice in the HFþT0901317 group
were fed an HF diet for four weeks and administered
T0901317 (Cayman Chemical Co., Ann Arbor, MI, USA)
solubilized in DMSO i.p. once a day for the ﬁnal ﬁve days;
and (iv) the mice in the novel NASH model group were fed
an HF diet for four weeks and administered both CCl4 and
T0901317, as described above. The CCl4 dose was 0.1mL/
kg, and the T0901317 dose was 2.5mg/kg.
Twenty-four hours after the ﬁnal administration of CCl4 or
T0901317, the mice were killed by exsanguination under
isoﬂurane anesthesia. Blood samples were collected from
the orbital capillary and centrifuged at 3,000 rpm for 10min
to isolate the serum. Each sample was stored at 30°C
until analysis. The liver was rapidly removed and weighed.
The right medial lobe of the liver was immediately ﬁxed in
10% neutral-buffered formalin for further histological
examination.
Histological analysis
The ﬁxed liver tissues were processed and embedded in
parafﬁn using standard methods. The liver tissues were
assessed by cutting into 2mm thick parafﬁn sections,
staining with haematoxylin and eosin, and evaluating the
extent of inﬂammation and hepatocellular ballooning. Fibro-
sis was evaluated by Masson's trichrome and Sirius red
staining. Steatosis was evaluated by Oil Red O staining.
The steatosis area was quantiﬁed using a BZ-X710 hybrid
cell count system (KEYENCE, Corp., Osaka, Japan). For
each section, at least ten non-consecutive random digital
images were obtained. The liver specimens were evaluated
by an experienced pathologist in a blinded fashion, and the
severity of hepatocellular steatosis, inﬂammation and bal-
looning was assessed using the following NAFLD activity
scores (NAS). With respect to hepatocellular steatosis, the
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specimens were classiﬁed into grades 0–3 (grade 0,
steatosis occupied less than 5% of the hepatic parenchyma;
grade 1, steatosis occupied 6–33% of the hepatic paren-
chyma; grade 2, steatosis occupied 34–66% of the hepatic
parenchyma; and grade 3, steatosis occupied more than
66% of the hepatic parenchyma). In terms of inﬂammatory
cell inﬁltration, the specimens were classiﬁed as grades 0–3
(grade 0, no inﬁltration; grade 1, one to two foci per 200
ﬁeld; grade 2, three to four foci per 200 ﬁeld; and grade 3,
more than four foci per 200 ﬁeld). With respect to
hepatocellular ballooning, the specimens were classiﬁed
into grades 0–2 (grade 0, no ballooning; grade 1, few
balloon cells; and grade 2, many cells/prominent balloon-
ing). Hepatic ﬁbrosis was classiﬁed as stage 0–4 (stage 0,
no ﬁbrosis; stage 1, mild, perisinusoidal or periportal
ﬁbrosis; stage 2, moderate, perisinusoidal and periportal
ﬁbrosis; stage 3, bridging ﬁbrosis; and stage 4, cirrhosis).19
Biochemical analysis
The serum levels of aspartate aminotransferase (AST),
alanine aminotransferase (ALT), triglyceride (TG), and total
cholesterol (T-CHO) were measured with a FUJI
DRI-CHEM 7000V serum multiple biochemical analyser
(Fujiﬁlm, Co. Tokyo, Japan).
The serum levels of tumor necrosis factor alpha (TNF-a)
and interleukin-6 (IL-6) were measured using a mouse
enzyme-linked immunosorbent assay (ELISA) kit (BioLe-
gend, Inc., San Diego, CA, USA).
Insulin tolerance test (ITT)
Four groups of mice subjected to the same regimen (n¼5
per group) were assessed using the ITT. The mice were
fasted for 4 h before the injection of insulin (Humulin R,
0.75U/kg, i.p.; Eli Lilly, Co., Kobe, Japan). The blood
glucose levels in the tail vein blood were measured 0, 15,
30, 60, 90 and 120min after the insulin injection.
Gene expression analysis
Liver tissue samples were freshly collected and immediately
frozen at 30°C until use. The frozen liver samples were
homogenized, and total RNA was isolated from whole cells
using a NucleoSpin RNA kit (Takara Bio, Inc., Otsu, Japan).
The RNA concentrations were determined by measuring the
absorbance at 260/280 nm with a NanoDrop Spectropho-
tometer (Thermo Fisher Scientiﬁc, Inc., Wilmington, DE,
USA). The synthesis of complementary DNA was performed
using AMV Reverse Transcriptase (Promega, Corp., Madi-
son, WI, USA) and random primers (Takara Bio, Inc. Otsu,
Japan). Brieﬂy, a mixture of 1mM dNTPs (Fermentas Life
Sciences, Inc., Burlington, ON, Canada), 0.025mg/mL
random primers, 0.25U/mL reverse transcriptase, and
500ng of total RNA was incubated at 30°C for 10min, 37°C
for 60min, 95°C for 5min and at 4°C prior to storage at
80°C.
The primers for RT-PCR were designed using Primer
Express software for Real-Time PCR ver. 3.0 (Applied
Biosystems, Inc., Foster City, CA, USA) based on the
sequences available in GenBank. The primers were pur-
chased from Hokkaido System Science Co., Ltd. (Hokkaido,
Japan) and Takara Bio, Inc. (Otsu, Japan). The Srebp-1c
primer sequences were 5’-GCAGCCACCATCTAGCCTG-3’
and 5’-CAGCAGTGAGTCTGCCTTGAT-3’. The Fas primer
sequences were 5’-GGAGGTGGTGATAGCCGGTAT-3’
and 5’-TGGGTAATCCATAGAGCCCAG-3’, and the ApoB
primer sequences were 5’-TTGGCAAACTGCATAGCATCC-
3’ and 5’-TCAAATTGGGACTCTCCTTTAGC-3’. The Gstm3
primer sequences were 5’-CATCCGCTTGCTCCTGGAATA-
3’ and 5’-GATGGCATTGCTCTGGGTGA-3’. The Scd1
primer sequences were 5’-TGTCTGACCTGAAAGCCGA-
GAA-3’ and 5’-AGCACCAGAGTGTATCGCAAGAA-3’. The
Scd2 primer sequences were 5’-GCTGCATTTGGGAGC
CTTGTA-3’ and 5’-CCATGGTGTTGGCAATGATGA-3’. The
Ly6d primer sequences were 5’-AGCTCTGCTCGTCCTCC
TTGTC-3’ and 5’-TCCTCACCAGGTTCCCATTCA-3’, and
the Lepr primer sequences were 5’-GGCACCATTTCCGCT
TCAATA-3’ and 5’-ACCAGCAGAGATGTAGCTGAGACAA-
3’, and the GAPDH primer sequences were 5’-TGCA
TCCTGCACCACCAACT-3’ and 5’-AACACGGAAGGCCA
TGCCAG-3’. Glyceraldehyde-3-phosohate dehydrogenase
(GAPDH) was used as an endogenous control. RT-PCR
was performed using SYBR-Green Real-time PCR Master
Mix-Plus (Toyobo Co., Ltd., Osaka, Japan) and an Applied
Biosystems 7300 Real-time PCR system (Applied Biosys-
tems, Inc., Foster City, CA, USA) as recommended by the
manufacturers.20
Microarray analysis
A DNA microarray analysis was conducted using RNA
samples isolated from liver tissues from the HF group and
the novel NASH model group. Labelled cRNA was synthe-
sized from 100ng of total RNA using a GeneChip 3’ IVT
Plus Reagent Kit (Affymetrix, Inc., Santa Clara, CA, USA)
according to the manufacturer's recommended protocol.
Fragmented and labelled cRNA (7.5mg) was hybridized to
an Affymetrix Mouse MG-430 PM Array Strip (Affymetrix)
for 16 h at 45°C. The strips were washed and stained using
a GeneAtlas Fluidics Station 400 (Affymetrix), and the
resulting images were scanned using a GeneAtlas Imaging
Station (Affymetrix). Probe-level analysis, including
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background subtraction and quantile normalization, was
conducted using the robust multi-array average algorithm
(RMA) with Affymetrix Expression Console Software 1.4
(Affymetrix). The gene expression proﬁle of the novel NASH
model was compared with that of the HF group. Genes
showing a more than two-fold increase in expression were
classiﬁed as upregulated genes and less than 0.5 fold
decrease in expression were classiﬁed as downregulated.
Statistical analysis
All data are expressed as the mean standard deviation.
Statistical analyses were conducted using PRISM. Inter-
group differences were assessed by one-way analysis of
variance (ANOVA) with the Holm-Sidak post-test. Pairwise
comparisons of the ITT results were performed using
Student's t-test. In all cases, P values less than 0.05 were
considered to indicate statistical signiﬁcance.
RESULTS
The novel NASH model developed liver injury,
dyslipidaemia and hypercytokinaemia
Findings at laparotomy and gross appearance of the liver
There was no ﬁndings of necrosis or inﬂammation at the
intraperitoneal injection site. The livers of the novel NASH
model group indicated a whitish colour and an uneven
surface that could be recognized even with the naked eye
and was markedly enlarged relative to the other groups
(Fig. 1a).
Body and liver weight
Table 1 indicates the body weights, liver weights and liver-
to-body weight ratios of the mice. The ﬁnal body weight was
increased in all the groups relative to the initial body weight.
The ﬁnal and initial body weight in the CCl4 group and the
novel NASH group was nearly to the mice fed the normal
diet (data was not shown). The liver weight and liver-to-
body weight ratio were signiﬁcantly higher in the novel
NASH model group than in the other groups.
Serum parameters
Table 1 indicates the serum parameters responsible for liver
injury, lipid metabolism and inﬂammatory cytokines in mice.
The serum ALT and AST levels were signiﬁcantly increased in
the HFþCCl4 group relative to the other groups and increased
in the novel NASH model group relative to the HF and
HFþT0901317 groups. Furthermore, the serum TG level was
signiﬁcantly increased in the novel NASH model group relative
to the other groups. The serum TNF-a and IL-6 concentrations
were measured as indicators of circulating inﬂammation, and
their levels were signiﬁcantly higher in the novel NASH model
group relative to the other groups.
Liver expression of genes involved in lipid metabolism
Figure 1b indicates the mRNA levels of Srebp-1c, Fas and
ApoB. Srebp-1c and Fas are related to de novo lipogenesis
in the liver, whereas ApoB is related to lipid transport in the
liver. The mRNA expression levels of Srebp-1c and Fas
were signiﬁcantly upregulated in the HFþT0901317 and
novel NASH model groups relative to the HF and HFþCCl4
groups. The mRNA expression level of ApoB was signiﬁ-
cantly downregulated in the novel NASH model group
relative to the other groups.
Insulin sensitivity
Insulin resistance was evaluated using the ITT. The glucose
level after insulin injection remained high in the novel NASH
model group (Fig. 2a). The glucose level measured in the
novel NASH model group was signiﬁcantly higher than that
of the HF group at 60min, 90min and 120min, and the area
under the curve of the novel NASH model group was
signiﬁcantly higher than that of the HF group (Fig. 2b).
Histological ﬁndings
Figure 3a indicates the liver histology of each group. The
novel NASH model group developed macrovesicular
hepatic steatosis, ballooning hepatocyte with Mallory-Denk
bodies, lobular inﬂammation and bridging ﬁbrosis (Fig. 3b).
In the novel NASH group, hepatic steatosis was found in
the whole liver. The steatosis area in the liver was
signiﬁcantly larger in the novel NASH model group relative
to the other groups (Fig. 3c). In the novel NASH group, the
lobular inﬂammation was found in zone 1 in the liver and
the hepatic ﬁbrosis was found from zone 1 to zone 3. The
average values of the NAS and the stage of hepatic ﬁbrosis
obtained for the novel NASH model group were 6.6 and 2.6,
respectively, and both values were signiﬁcantly higher than
those found for the other groups (Fig. 3d).
Liver expression of genes involved in NASH
Table 2 indicates the results of the microarray analysis.
Eight genes were signiﬁcantly upregulated and ﬁve genes
were signiﬁcantly downregulated in the novel NASH
group. Five genes (Gstm3, Scd1. Scd2, Ly6d, and Lepr)
related to NASH were detected. Furthermore, the
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expression of these ﬁve genes in all the groups was
further conﬁrmed by real-time PCR. The mRNA expres-
sion levels of all the tested genes were signiﬁcantly
upregulated in the novel NASH model group relative to
the other groups (Fig. 4).
DISCUSSION
Although several NASH models have been reported, few
models fully reﬂect the histopathology and pathophysiology
of human NASH.7–11 The MCD model and the HF diet
Figure 1 Macroscopic changes of the liver and changes in the expression of genes involved in lipid metabolism in the liver. (a)
Photographs of liver tissue. Upper panel, photographs taken at laparotomy; lower panel, photographs taken immediately after removal (bar
length¼1 cm). (b) Parameters of lipid metabolism. (a) mRNA expression of Srebp-1c in the liver. (b) mRNA expression of Fas in the liver. c:
mRNA expression of ApoB in the liver. The data are expressed as the meansSDs (n¼5).  P < 0.01 vs the HF and HFþCCl4 groups;
## P<0.01 vs the other groups.
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model have been widely used for basic studies of NASH.
However, these models do not closely resemble human
NASH in terms of histopathological ﬁndings and insulin
resistance.2 In this study, we established a novel experi-
mental NASH model using a combination of an HF diet,
CCl4 and T0901317, and the novel model exhibits similar
histopathology and pathophysiology to human NASH. Spe-
ciﬁcally, macrovesicular hepatic steatosis, ballooning hep-
atocytes, Mallory-Denk bodies, lobular inﬂammation and
bridging ﬁbrosis were observed in our novel NASH model.
These manifestations are similar to those found in human
NASH. Additionally, this model exhibited metabolic abnor-
malities such as insulin resistance and dyslipidemia. These
features are the essential requisites for an ideal NASH
model.15 Although CCl4 is usually used in the classical
hepatic ﬁbrotic model and is administered at 1mL/kg, it is
too much as a NASH model. Thus, we adjusted the dosage
of CCl4 to 0.1mL/kg. Our novel NASH model led to
steatohepatitis with severe hepatic ﬁbrosis in the short term.
Furthermore, this model also developed insulin resistance.
Thus, this model is expected to be useful for basic research
on NASH.
To date, the pathogenesis of NASH has not been
completely elucidated. The ‘two-hit’ theory is the most
widely used to explain the pathogenesis and progression
of NASH; the ﬁrst hit causes fat accumulation in hepato-
cytes, and the second hit causes inﬂammation and
ﬁbrosis.21 However, the pathogenesis of NASH is too
complex to be completely explained by this theory.
Although the pathogenesis of NASH remains poorly
understood, proinﬂammatory cytokines appear to play an
important role in the development of NASH,22 with TNF-a
and IL-6 showing strong involvement in NASH pathogene-
sis.22 In a clinical setting, the serum TNF-a and IL-6
levels are signiﬁcantly increased in NASH relative to
simple steatosis.23 This ﬁnding suggests that high serum
TNF-a and IL-6 levels are involved in the development of
NASH. Tomita et al. reported that the serum TNF-a level
is a predictor of NASH.24 In our study, we found that the
serum TNF-a and IL-6 levels are signiﬁcantly increased in
the novel NASH model group. These factors are important
components of an ideal NASH model.
Table 1 Body weight, liver weight and plasma biochemical parameters
HF HFþCCl4 HFþT0901317 Novel NASH model
Body weight (g)
Initial 23.21.1 22.90.8 22.30.5 22.40.4
Final 31.71.8 30.40.9 27.61.1 27.01.8
Liver weight (mg) 1339151 1546128 1798167 2491253
Liver/body weight (%) 4.240.49 5.080.33 6.500.51 9.210.37
Biochemical parameters
ALT (U/L) 58.347.4 1425347.4## 83.730.6 739.6494.2
AST (U/L) 79.239.6 613.8139.9 107.727.4 620.8251.4
TG (mg/dL) 128.822.3 145.246.2 172.235.3 509.4252.3##
T-CHO (mg/dL) 129.310.5 157.514.8 198.76.1 125.418.2
Inflammatory parameters
TNF-a (pg/mL) 4.722.88 5.300.93 3.560.64 10.803.48##
IL-6 (pg/mL) 4.792.06 23.659.41 11.606.67 372.12107.36##
Note: ALT, alanine aminotransferase; AST, aspartate aminotransferase; TG, triglyceride; T-CHO, total cholesterol; TNFa, tumour necrosis factor-a;
IL-6, interleukin-6. Data are meanSD (n¼ 5). P < 0.05,  P <0.01 vs HF group (control). ## P < 0.01 vs other groups.
Figure 2 Evaluation of insulin sensitivity. (a) Results of insulin
tolerance test. (b) Area under the curve. The data are expressed
as the meansSDs (n¼5). P<0.05 for the comparison of the
novel NASH model group vs the HF group.
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Fat accumulation in hepatocytes plays a central role in
the progression of NASH.25 This accumulation occurs when
the rate of fatty acid import exceeds the rate of export. In
our model, the following mechanisms appear to contribute
to lipid accumulation in the liver: (i) an HF diet increases the
uptake of fatty acids by hepatocytes; (ii) the administration
of T0901317 increases de novo fatty acid and triglyceride
synthesis in the liver; and (iii) the rates of very-low-density
Figure 3 (Continued).
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lipoprotein (VLDL) synthesis and triglyceride export are
decreased. Our study demonstrated that the mRNA expres-
sion of Srebp-1c and Fas (a marker of de novo fatty acids
synthesis) was upregulated in the two groups administered
T0901317. In contrast, the mRNA expression of ApoB (a
marker of triglyceride export) was downregulated in only the
novel NASH model group. Although the detailed mechanism
remains unclear, increased de novo fatty acid synthesis and
decreased triglyceride export promote fat accumulation in
the liver. These effects might have played a key role in the
progression of NASH in our model. Further studies are
necessary to clarify the precise pathogenesis of NASH.
In addition to the histopathological ﬁndings, insulin resis-
tance is an important feature of human NASH. In fact,
insulin resistance is a frequent ﬁnding in NASH patients
despite the absence of overt diabetes and is known to play
a signiﬁcant role in obesity-related metabolic disturban-
ces.26 We used the ITT to evaluate insulin resistance27 and
found that the novel NASH model developed prominent
overall insulin resistance. Several in vitro studies have
demonstrated that IL-6 promotes insulin resistance,28–31
and studies in animal models have also shown a correlation
between IL-6 and insulin resistance.32,33 The increased
serum level of IL-6 observed in our model might have
inﬂuenced the development of insulin resistance.
We performed a microarray analysis for the evaluation of
gene expression in the novel NASH model and found that
several genes were upregulated in the novel NASH model
group relative to the HF group. Furthermore, we conﬁrmed
that ﬁve genes (Gstm3, Scd1, Scd2, Ly6d, and Lepr)
related to NASH were signiﬁcantly upregulated in the novel
NASH model group relative to the other groups. Gstm3 is
related to oxidative stress, and oxidative stress induced by
the overproduction of reactive oxygen species (ROS) is
necessary for the development of NASH.21,34 Glutathione
S-transferases (GSTs), including Gstm3, detoxify xenobiot-
ics.35 Thus, the upregulation of this gene suggests that
ROS are overproduced in mice. Scd1 and Scd2 are related
to lipogenesis and have been shown to be upregulated in
NASH animal models.36 Leptin is involved in the
3
Figure 3. Histopathological ﬁndings. (a) Representative liver histopathology. Upper panel, the results of haematoxylin and eosin staining;
upper middle panel, the results of Masson's trichrome staining; lower middle panel, the results of Sirius red staining; lower panel, the results
of Oil Red O staining. HE, haematoxylin and eosin staining; MT, Masson's trichrome staining; SR, Sirius red staining; OR, Oil Red O
staining; CV, central vein; PV, portal vein. (Original magniﬁcation 200 in HE, MT and SR, 400 in OR). (b) Representative liver
histopathological ﬁndings of haematoxylin and eosin staining and Oil red O staining of the novel NASH model group: (a) hepatocyte
ballooning, (b) Mallory-Denk bodies, (c) inﬂammation and (d) macrovesicular steatosis. (c) Rate of hepatic steatosis area as indicated by Oil
Red O staining in each group. The data are expressed as the meansSDs (n¼5).  P<0.0001 vs the other groups. (d)
Histopathological evaluation of the liver based on the NAFLD activity score (NAS; 0–8 points). The scoring was based on the presence of
steatosis (0–3 points), inﬂammation (0–3 points) and ballooning (0–2 points). NASH was diagnosed when the number of total points
exceeded 5. Fibrosis of the liver was evaluated by the Kleiner classiﬁcation (0–3 points). Each group included n¼5.
Table 2 Microarray analysis of liver tissues from mice in the novel NASH model group and HF group
Relation Gene symbol Gene Name (Description)
Fold
change P-value Regulation
CYP4A11 Cytochrome P450, family 4, subfamily A, polypeptide 11 2.78 0.005 Up
Oxidative
stress
Gstm3 Glutathione S-transferase mu 3 2.69 0.013 Up
Lipogenesis Scd2 Stearoyl-CoA desaturase (delta-9-desaturase) 2.67 0.001 Up
RAD51B RAD51 paralog B 2.34 0.007 Up
Hepatic fibrosis LEPR leptin receptor 2.28 0.025 Up
Hepatic
steatosis
LY6D lymphocyte antigen 6 complex, locus D 2.26 0.001 Up
Lipogenesis Scd1 Stearoyl-CoA desaturase (delta-9-desaturase) 2.09 0.003 Up
BIRC5 baculoviral IAP repeat containing 5 2.03 0.016 Up
MOXD1 monooxygenase, DBH-like 1 0.47 0.041 Down
m_1500017E21Rik RIKEN cDNA 1500017E21 gene 0.47 0.002 Down
m_Serpina4-ps1 serine (or cysteine) peptidase inhibitor, clade A, member 4,
pseudogene
0.47 0.041 Down
UGT2B28 UDP glucuronosyltransferase 2 family, polypeptide B28 0.46 0.002 Down
m_Mup3 Major urinary protein 3 0.45 0.001 Down
Note: Liver samples from two mice in the novel NASH model group and HF group were used for the microarray analysis. Five genes related to
NASH were upregulated in the novel NASH model group more than 2-fold compared to the corresponding genes in the HF group.
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pathogenesis of NASH due to its important modulatory
effects on the regulation of body weight and appetite and in
preventing fat accumulation in the liver.37 Medici et al.
reported that the soluble leptin receptor (SLR) is positively
correlated with the stage of hepatic ﬁbrosis in humans.38
Guillen et al. reported that Ly6d gene expression is
positively correlated with hepatic steatosis in animals.39
Thus, several genes related to the development of NASH
were found to be upregulated in the novel NASH model
group. This ﬁnding supports the conclusion that our model
exhibits the transcriptomic features of NASH.
In conclusion, we established a novel experimental NASH
model through feeding an HF diet and administering both
CCl4 and T0901317 to mice. Figure 5 indicates the mecha-
nism of the progression of NASH in the novel animal model.
NASH is diagnosed based on histological ﬁndings, and
clinical insulin resistance and hypercytokinaemia play cen-
tral roles in its progression. Our novel NASH model exhibits
these important features and the associated transcriptomic
characteristics. We believe that our animal model, which
has the characteristics of human NASH, will be useful for
basic research on NASH.
Figure 4 Genes involved in NASH development that were upregulated in the microarray analysis. (a) mRNA expression of Gsmt3 in the
liver. (b) mRNA expression of Scd1 in the liver. (c) mRNA expression of Scd2 in the liver. (d) mRNA expression of Ly6d in the liver. (e)
mRNA expression of Lepr in the liver. The data are expressed as the meansSDs (n¼5).  P<0.01 vs the other groups.
© 2017 The Authors. Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd
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